A Phase 2 interventional study of S1B-408 in Orgasmic Disorder, sponsored by S1 Biopharma, Inc.. Not yet recruiting. Open to female participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by S1 Biopharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is the first clinical trial of S1B-408 in women with sexual dysfunction. A prior 4-week trial in premenopausal women with Hypoactive Sexual Desire Disorder showed that orgasmic function improved with Lorexys (TM). This pilot trial tests for improvement in orgasmic function, safety, and tolerability of a different but related test article.
S1B-408 is a proprietary combination of agents proven safe and effective in other CNS indications. The combination drug is aimed at treating women's sexual dysfunction disorders. Its two components each have pro-sexual effects. However, the efficacy of each when given alone has been limited. Moreover, each component has side effects which, while benign, may limit the drug's utility: activation (agitation, anxiety, insomnia) with one; sedation (somnolence, fatigue, etc) with the other.
The goal of this trial is to show that, when formulated in the proper (fixed) ratio, the combination of these two drugs strengthens their pro-sexual effects for orgasmic dysfunction while mitigating the opposing side effect profiles.
For this pilot study, the goal for exposure is to seek rapid onset of action with minimal dosing.
138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.
This study's planned enrollment of 30 is below the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.
Browse Sexual Dysfunctions, Psychological studies →S1 Biopharma, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of S1B-408 with up-titration of one of its components after one week as needed and tolerated
Drug: S1B-408
Medication with multiple monoamine activities
Female Sexual Function Index (FSFI): orgasm domain
sum of 3 items on orgasmic frequency, difficulty, and satisfaction, each rated 0 or 1 (worst) to 5 (best)
Time frame: 7 or 28 day recall
Changes in Sexual Function Questionnaire (CSFQ): orgasm
sum of 3 items on orgasmic frequency, pleasure, and ability, each rated 1 (worst) to 5 (best)
Time frame: 7 day recall
CSFQ total score
sum of 14 items on all aspects of female sexual response, scored from 14 to 70 (best)
Time frame: "now" or 7 day recall
FSFI total score
sum of 19 items on 6 aspects of female sexual response, scored from 4 (worst) to 95 (best)
Time frame: Prior 7 or 28 days
Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) items 13, 14, and 15 scores
3 items on sexual distress re desire, arousal, and orgasm, each scored from 0 to 4 (best)
Time frame: Prior 7 or 28 days
Sexual Activity Log (SAL), orgasms
Sexual Activity Log count of orgasms
Time frame: 1-7 day recall
SAL proportion of sexual activities with orgasm
Sexual Activity Log count of orgasms over times engaged in sex; best would be 1.0
Time frame: 1-7 day recall
Sexual Activity Log (SAL) satisfying sexual events
Count of sexual events that were satisfying
Time frame: 1-7 day recall
Patient's Global Impression of Change
single question rated from 1 (best) to 7 (worst) asking improvement vs none or worsening
Time frame: 4 weeks
Safety: adverse events
All adverse outcomes in clinician's judgment in answer to a question: How do you feel? or in interpreting objective information about the patient
Time frame: 4-week recall
pulse rate
number of heart beats per minute effective enough to reach the arm
Time frame: one fourth to one half minute
Blood pressure
pressures in mm of mercury when a heartbeat reaches the arm and between heartbeats
Time frame: one half minute or less
Q-T interval
time in milliseconds between start and end of a contraction of the ventricles of the heart as measured by electrocardiogram (ECG)
Time frame: three heartbeats up to the number of heartbeats in 30 seconds
Cardiac rate
Number of contractions of the ventricles of the heart per minute as measured by ECG
Time frame: 1/2 to 1 minute
Columbia Suicide Severity Rating Scale, 6-item Screening/Triage version (C-SSRS-6)
6-item self-rating scale on suicidal ideas, intent and behavior monitored by clinician; "no" rather than "yes" answer to each item is best score
Time frame: prior 30 days
Patient Health Questionnaire-9 Symptom Checklist (PHQ-9)
9 items on depressive symptoms rated from 0 (best) to 3 (worst)
Time frame: prior 2 weeks
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexual Dysfunctions, Psychological →